Signos was last valued at $1B (post-money). It comes from the $20M Series C+ of May 2026. The company is private, so there is no listed share price.
1 valuation. The latest, $1B post-money, was set by the Series C+ in May 2026.
A private valuation is the price agreed in one transaction. The Signos valuation of $1B is a post-money figure from the Series C+ dated 27 May 2026 — the whole company measured after the $20M raised in that round was already inside it. Subtract the round and the pre-money view of the same deal is $980M .
The valuation holds until the next priced round or secondary sale. A private company founded in 2016 with roughly 200 people has no daily price and no order book between rounds.
The last valuation is $1B (post-money, May 2026).
Lead investors for each round are in the funding timeline.
The closest healthtech / diabetes peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
